BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington, DC (May 17 – 22, 2010).
The AMEP™ biotherapy is indicated for metastatic and invasive melanoma, an advanced skin cancer refractory to most treatments. Its original mechanism of action targets specific receptors (integrins) involved in tumor growth and in tumor angiogenesis.
The results presented at the ASGCT demonstrated regulatory preclinical efficacy and safety:
- Efficacy studies demonstrated that AMEPTM administration in human melanoma xenograft models induced a higher tumor growth inhibition than with Temozolomide, the standard chemotherapy used in metastatic melanoma treatment ;
- Safety and biodistribution studies showed a good overall tolerance with AMEP™ and a progressive elimination from tissues without accumulation.
Based on these results, AMEP™ phase I clinical trial has been initiated for the treatment of advanced and metastatic melanoma in France, Denmark and Slovenia.
BioAlliance has been granted €6.4 million from OSEO (the French state innovation agency) which finances technological breakthrough projects.
BioAlliance Pharma SA